Telix Pharmaceuticals analysis: Fair value $17.14 USD vs current $17.50 AUD. High-growth radiopharmaceutical platform with 51.2% revenue growth, therapeutic pipeline worth $2.8bn risk-adjusted value, though execution risks and 8.4x leverage require careful assessment.
View noteHOLD rating with $3.81 fair value vs $4.21 current price. Strong growth prospects offset by integration risks and margin compression pressures.
View noteHOLD rating with $11.59 fair value vs $14.00 current price. Strong infrastructure franchise but elevated leverage and regulatory risks limit upside potential.
View noteSuper Retail Group trades at $16.21 vs fair value $13.56, facing digital disruption and margin pressure across four-brand specialty retail portfolio with 55% thesis failure probability.
View noteBUY rating with $1.04 fair value vs $0.54 current price. High-risk transformation story with 562% EBITDA growth but execution challenges.
View notePre-revenue gold explorer trading at A$0.047 vs A$0.191 fair value. Dual catalysts: systematic exploration across 1,000km² Eastern Goldfields tenure and US$50m arbitration award. High risk, asymmetric upside.
View noteHOLD rating with $1.78 fair value vs $1.99 current price. Strong 80% annuity model offset by margin compression risks and 53% valuation premium to peers.
View noteMedical device manufacturer with 35-40% oral appliance market share. Fair value $0.30 vs current $0.70. EBITDA margins compressing, manufacturing constraints binding.
View noteBUY rating with A$4.76 fair value vs A$2.36 current price. Strong balance sheet, operational excellence, 102% upside potential despite commodity volatility.
View noteSpeculative buy with 124% upside to $9.06 fair value. Binary TRL-6 catalyst Q4 2025. Revolutionary laser enrichment technology targeting 8% Western market share.
View noteHOLD rating on Sky Network Television. Fair value NZ$5.68 vs current NZ$2.58 (120% upside). Dominant 80% NZ pay-TV share, 8.5% yield, but 2030 sports rights renewal risk.
View noteElectrical contractor riding data centre wave faces inevitable margin compression. Fair value $1.55 vs current $2.97. EBITDA margins 9.0%, ROIC 84%, but competition emerging.
View note